ClinicalTrials.gg
CompletedNCT03936569Updated Jun 8, 2023

A Clinical Study to Assess the Plaque and Gingivitis Effects of a Stannous Fluoride Dentifrice

A Phase 4 interventional study of Marketed Toothpaste and Marketed Cavity Protection Toothpaste in Gingivitis, sponsored by Procter and Gamble. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-08.

Sponsored by Procter and Gamble · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Oct 2018, registered May 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Gingivitis by Procter and Gamble — none open to participants now, 2 under way, none of them phase 3. Gingivitis · Procter and Gamble.

Enrollment
8th of 18
90 · median 90
Started
2018
with 4 others
Phase 4
5 of 22
none open now
Registered
8th of 22
by date

Among the 22 studies in Gingivitis by Procter and Gamble, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2018, is one of 5 in phase 4, and was the 8th registered.

Gingivitis

631 studies on the registry are indexed under Gingivitis; 107 are open to participants now.

Browse Gingivitis studies →

Open to participants now

None of the 22 studies in Gingivitis by Procter and Gamble is open now. The open studies under Gingivitis, anywhere →

Where they have run

Who these studies take

Of the 53 Gingivitis studies recruiting now, 15 (28%) set no upper age limit and 36 (68%) stop at 75 or younger; 11 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies in Gingivitis by Procter and Gamble as a file.
02

Study summary

The objective of this clinical study is to assess the effects of a 0.454% stannous fluoride dentifrice on gingivitis and plaque after 3 months when compared to a negative control.

03

Conditions studied

  • Gingivitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be at least 18 years of age;
  • Provide written prior to participation and be given a signed copy of the informed consent form;
  • Be in general good health as determined by the Investigator based on a review of the health history/update for participation in the trial;
  • Have at least 16 gradable teeth;
  • Agree to return for scheduled visits and follow the study procedures;
  • Agree to refrain from use of any non-study oral hygiene products for the duration of the study;
  • Agree to delay any elective dentistry, including dental prophylaxis, until the completion of the study.

Exclusion criteria

Exclusion Criteria:

  • Having taken antibiotic, anti-inflammatory, or anti-coagulant medications within 4 weeks of the Baseline Visit;
  • Have any oral conditions that could interfere with study compliance and/or examination procedures, such as widespread caries, soft or hard tissue tumor of the oral cavity, or advanced periodontal disease;
  • Removable oral appliances;
  • Fixed facial or lingual orthodontic appliances;
  • Self-reported pregnancy or lactation;
  • Any diseases or condition that might interfere with the safe participation in the study; and
  • Inability to undergo study procedures.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Marketed Stannous Fluoride Toothpaste

    Brush twice daily

    Drug: Marketed Toothpaste

  • Placebo comparator
    Marketed Cavity Protection Toothpaste

    Brush twice daily

    Drug: Marketed Cavity Protection Toothpaste

Interventions

  • DrugMarketed Toothpaste

    Marketed stannous fluoride (0.454%) toothpaste

  • DrugMarketed Cavity Protection Toothpaste

    Marketed sodium monofluorophosphate (0.76 %) toothpaste

06

What researchers measure

Primary outcomes

  1. Löe-Silness Gingivitis Evaluation

    Löe-Silness Gingivitis Evaluation is a validated assessment of gingival health looking at inflammation and bleeding based on a 4 point range 0 (normal gingiva) to 3 (severe inflammation).

    Time frame: Baseline

  2. Löe-Silness Gingivitis Evaluation

    Löe-Silness Gingivitis Evaluation is a validated assessment of gingival health looking at inflammation and bleeding based on a 4 point range 0 (normal gingiva) to 3 (severe inflammation).

    Time frame: 1 Month

  3. Löe-Silness Gingivitis Evaluation

    Löe-Silness Gingivitis Evaluation is a validated assessment of gingival health looking at inflammation and bleeding based on a 4 point range 0 (normal gingiva) to 3 (severe inflammation).

    Time frame: 3 Months

Secondary outcomes

  1. Turesky Modified Quigley-Hein Index

    The Turesky Modified Quigley-Hein Index is a validated assessment of dental plaque based on a scale of 0 (no plaque/debris) to 5 (plaque covering two-thirds or more of the side of the crown or tooth).

    Time frame: Baseline

  2. Turesky Modified Quigley-Hein Index

    The Turesky Modified Quigley-Hein Index is a validated assessment of dental plaque based on a scale of 0 (no plaque/debris) to 5 (plaque covering two-thirds or more of the side of the crown or tooth).

    Time frame: 1 Month

  3. Turesky Modified Quigley-Hein Index

    The Turesky Modified Quigley-Hein Index is a validated assessment of dental plaque based on a scale of 0 (no plaque/debris) to 5 (plaque covering two-thirds or more of the side of the crown or tooth).

    Time frame: 3 Months

07

Study locations

1 site
  • Silverstone Research Group
    Las Vegas, Nevada 89146, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Jan 2019, 2 months.

Of 25 phase 4 interventional studies under Gingivitis, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 4. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2019
First posted
May 3, 2019
StartActual
Oct 29, 2018
Primary completionActual
Jan 25, 2019
CompletionActual
Jan 25, 2019
Last update
Jun 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03936569
Lead sponsor
Procter and Gamble
Responsible party
Sponsor
First posted
May 3, 2019
Start date
Oct 29, 2018
Primary completion
Jan 25, 2019
Completion
Jan 25, 2019
Last update
Jun 8, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion